Cyclopharm is an Australian ASX listed medical device company founded in 1986. It specializes in the field of nuclear medicine, with its foundation product, Technegas, being a lung ventilation imaging agent. Technegas stands out for its use in diagnosing Pulmonary Embolism (PE) and is also being investigated for additional indications such as the diagnosis and management of COPD, Asthma, and CTEPH, as well as the effectiveness of lung reduction interventions.
Cyclopharm's new product, Ultralute, set to be released later in 2016, is a first-in-class proprietary technology designed to improve the efficiency, productivity, and healthcare economics in the production of radiopharmaceuticals.
The company's technology involves a structured ultra-fine dispersion of radioactive labeled carbon, which is produced by drying Technetium-99m in a carbon crucible and then heating the isotope for a few seconds at around 2,700oC in a Technegas Generator. The resultant gas-like substance is inhaled by the patient via a consumable product known as a Patient Administration Set (PAS).
Ultimately, the inhaled Technegas particles enable multiple views and tomography imaging under a gamma or single photon emission computed tomography (SPECT) camera for superior functional ventilation imaging.
There is no investment information
No recent news or press coverage available for Cyclopharm.
We care about your data, and we'd love to use cookies make your experience better.
